Former cardiothoracic surgeon and seasoned biopharma executive steps in as lead candidate S-969 moves closer to IND filing
RENO, NV, UNITED STATES, July 17, 2026 /EINPresswire.com/ — Sarcomatrix Therapeutics, a biopharmaceutical firm creating novel treatments for Duchenne muscular dystrophy (DMD), has announced the hiring of Jeff Myers, M.D., Ph.D., as Chief Medical Officer. Dr. Myers joins the organization as Sarcomatrix progresses its lead small-molecule candidate, S-969, toward an Investigational New Drug (IND) submission and initial human clinical trials.
Dr. Myers brings over 15 years of executive-level experience overseeing clinical development, regulatory strategy, medical affairs, and global clinical operations within biotechnology companies focused on innovative therapies. Before joining Sarcomatrix, he held senior executive positions, including Chief Medical Officer at Beyond Air, Revolo Biotherapeutics, and Portola Pharmaceuticals. Earlier in his career, he worked as a congenital cardiothoracic surgeon and served as Chief of Pediatric Cardiac Surgery at both Massachusetts General Hospital and Tulane University.
"Jeff's track record of steering first-in-class therapies from development through to clinical execution makes him an outstanding addition to our leadership team," said David Craig, Co-Founder and Chief Executive Officer of Sarcomatrix Therapeutics. "As we get ready to enter the clinic, his knowledge of clinical development, regulatory strategy, and translational medicine will be crucial as we move S-969 toward patients affected by Duchenne muscular dystrophy."
In his role as Chief Medical Officer, Dr. Myers will offer strategic direction for Sarcomatrix's clinical development program. This includes finalizing the Phase I clinical approach, supporting regulatory discussions, guiding CRO selection, and helping drive the company's lead therapeutic candidate toward clinical testing.
"I am thrilled to join Sarcomatrix at such a pivotal moment in the company's progress," said Dr. Myers. "The scientific basis behind S-969 and the chance to potentially enhance outcomes for individuals living with Duchenne muscular dystrophy are extremely compelling. I look forward to collaborating with David and the rest of the team as we move from preclinical work into the clinic."
S-969 is an investigational oral small-molecule therapy being developed to target the underlying muscle degeneration linked to Duchenne muscular dystrophy, a rare, progressive neuromuscular condition that affects roughly one in every 3,500 to 5,000 male births globally.
About Sarcomatrix Therapeutics
Sarcomatrix Therapeutics is a biopharmaceutical company creating novel oral therapies for Duchenne muscular dystrophy and related neuromuscular disorders. The company's lead investigational candidate, S-969, is intended to enhance muscle function and slow disease progression through a distinct mechanism of action. Sarcomatrix is advancing S-969 toward clinical development with the aim of delivering accessible therapies that improve the lives of patients suffering from devastating neuromuscular diseases.
Media Contact
Madelyn De Los Santos
Putnam Insights LLC
madelyn@putnaminsights.com
